Abstract： Objective To investigate the efficacy of bevacizumab combined with TP chemotherapy(paclitaxel+cispla-tin)in the treatment of advanced non-small cell lung cancer(NSCLC)and its influence on prognosis.Methods 78 patients with advanced NSCLC were randomly divided into group A(39 cases,receiving TP chemotherapy)and group B(39 cases,receiving TP chemotherapy+bevacizumab).The objective response rate(ORR),disease control rate(DCR)and serum tumor markers levels(vascular endothelial growth factor,VEGF;cytokeratin 19 fragment,CYFRA21-1;carcinoembryonic antigen,CEA)were compared between the 2 groups.Adverse reactions such as liver and renal dysfunction,leukopenia,neutropenia,thrombocytopenia and gastro-intestinal reactions were recorded during treatment.Patients were followed up from the start of treatment,and 5-year survival,pro-gression-free survival(PFS)and overall survival(OS)of the 2 groups were counted.Results ORR and DCR of group B were 58.97％and 89.74％,respectively,higher than 35.90％and 71.79％of group A(P＜0.05).After treatment,serum levels of VEGF,CYFRA21-1 and CEA in the 2 groups decreased,and group B was lower than group A(P＜0.05).There were no signifi-cant differences in the incidence of liver and renal dysfunction,leukopenia,neutropenia,thrombocytopenia and gastrointestinal re-actions between the 2 groups(P＜0.05).The 5-year survival rate of group B was 20.51％,which was not significantly different from group A(12.82％)(P＞0.05).The median PFS were longer in group B than in group A(8.9 vs 7.2 months)(P＜0.05);the median OS in group B was longer than that in group A(25.6 vs 17.9 months)(P＜0.05).Conclusion Compared with TP chemotherapy in the treatment of advanced NSCLC,combined bevacizumab can increase ORR and DCR,prolong PFS and OS,and reduce the levels of VEGF,CYFRA21-1 and CEA tumor markers.